The Role of the Immune System in Huntington’s Disease
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is characterized by a progressive course of disease until death 15–20 years after the first symptoms occur and is caused by a mutation with expanded CAG repeats in the huntingtin (htt) protein. Mutant htt (mhtt) in the striatum is assumed to be the main reason for neurodegeneration. Knowledge about pathophysiology has rapidly improved discussing influences of excitotoxicity, mitochondrial damage, free radicals, and inflammatory mechanisms. Both innate and adaptive immune systems may play an important role in HD. Activation of microglia with expression of proinflammatory cytokines, impaired migration of macrophages, and deposition of complement factors in the striatum indicate an activation of the innate immune system. As part of the adaptive immune system, dendritic cells (DCs) prime T-cell responses secreting inflammatory mediators. In HD, DCs may contain mhtt which brings the adaptive immune system into the focus of interest. These data underline an increasing interest in the peripheral immune system for pathomechanisms of HD. It is still unclear if neuroinflammation is a reactive process or if there is an active influence on disease progression. Further understanding the influence of inflammation in HD using mouse models may open various avenues for promising therapeutic approaches aiming at slowing disease progression or forestalling onset of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“several studies have indicated that mutated HTT has an important impact on microglia and neuroinflammation during HD pathogenesis (163).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · cited 1×
“Huntington’s disease (HD) is an autosomal dominantly inherited disorder with a trinucleotide CAG repeat expansion ≥36 in the exon 1 of the HD gene located on chromosome 4 [1].”
BackgroundM-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287 · cited 1×
“More recent findings further refined this concept and indicate that macrophages can be differentiated into M1 and M2 subtypes [53, 56].”
BackgroundMangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Development of Monocytes, Macrophages, and Dendritic Cells
Geissmann, F., Manz, M. G., Jung, S., Sieweke, M. H., Merad, M., & Ley, K. (2010) · Science · doi:10.1126/science.1178331 · Cited by 3,049
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“These cytokines inhibit macrophage activation but induce antibody production resulting in resolution of inflammation through endocytic clearance and trophic factor synthesis [57].”
BackgroundMellman, I., & Steinman, R. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00449-4 · Cited by 2,237
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Microglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858 · cited 1×
“Microglia are primary mediators of neuroinflammation [39, 40] and seem to be key players in the pathogenesis of neurodegenerative diseases [20].”
BackgroundMicroglia as a source and target of cytokines
Hanisch, U. (2002) · Glia · doi:10.1002/glia.10161 · Cited by 1,645 · cited 1×
“As downstream effects, an increase of caspase activity, intracellular calcium levels, and the production of reactive oxygen species and nitric oxide could be detected [48].”
BackgroundControl of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531 · cited 1×
“Notably, brain lysates of R6/2 HD mice display significantly higher levels of IL-1β than wild-type control [23, 74–76].”
BackgroundGrouard, G., Rissoan, M.-C., Filgueira, L., Durand, I., Banchereau, J., & Liu, Y.-J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.6.1101 · Cited by 1,189
Glutamate receptors, neurotoxicity and neurodegeneration
Lau, A., & Tymianski, M. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-010-0809-1 · Cited by 1,185
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 1×
“Own studies further revealed that DMF potentially exerts neuroprotective effects via induction of the transcription factor “nuclear factor E2-related factor 2” (Nrf2) and detoxification pathways [103].”
BackgroundSelf-citationAndrew, S. E., Paul Goldberg, Y., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., Squitieri, F., Lin, B., Kalchman, M. A., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-398 · Cited by 1,129
Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Broxmeyer, H. E., & Charo, I. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119798 · Cited by 1,096
Innate immunity in the central nervous system
Ransohoff, R. M., & Brown, M. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58644 · Cited by 1,034 · cited 3×
“Inflammasomes are activated by the cytoplasmic presence of microbial components, tissue-injury products, or inflammation-associated substances [84].”
BackgroundInfluentialBroad Expression of Toll-Like Receptors in the Human Central Nervous System
Bsibsi, M., Ravid, R., Gveric, D., & van Noort, J. M. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.1013 · Cited by 999
Novelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988) · Brain Research · doi:10.1016/0006-8993(88)90765-2 · Cited by 971
Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., Gage, F. H., & Glass, C. K. (2009) · Cell · doi:10.1016/j.cell.2009.01.038 · Cited by 957
In Vivo Analysis of Dendritic Cell Development and Homeostasis
Liu, K., Victora, G. D., Schwickert, T. A., Guermonprez, P., Meredith, M. M., Yao, K., Chu, F.-F., Randolph, G. J., Rudensky, A. Y., & Nussenzweig, M. (2009) · Science · doi:10.1126/science.1170540 · Cited by 952
Microglia as neuroprotective, immunocompetent cells of the CNS
Streit, W. J. (2002) · Glia · doi:10.1002/glia.10154 · Cited by 919
Specific Coupling of NMDA Receptor Activation to Nitric Oxide Neurotoxicity by PSD-95 Protein
Sattler, R., Xiong, Z., Lu, W.-Y., Hafner, M., MacDonald, J. F., & Tymianski, M. (1999) · Science · doi:10.1126/science.284.5421.1845 · Cited by 834
Hodgson, J. G., Agopyan, N., Gutekunst, C.-A., Leavitt, B. R., LePiane, F., Singaraja, R., Smith, D. J., Bissada, N., McCutcheon, K., Nasir, J., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80764-3 · Cited by 830
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Slow, E. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg169 · Cited by 800
Defects in Macrophage Recruitment and Host Defense in Mice Lacking the CCR2 Chemokine Receptor
Kurihara, T., Warr, G., Loy, J., & Bravo, R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.10.1757 · Cited by 717
Van Dyken, S. J., & Locksley, R. M. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095906 · Cited by 714
Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease
Snell, R. G., MacMillan, J. C., Cheadle, J. P., Fenton, I., Lazarou, L. P., Davies, P., MacDonald, M. E., Gusella, J. F., Harper, P. S., & Shaw, D. J. (1993) · Nature Genetics · doi:10.1038/ng0893-393 · Cited by 709
Waskow, C., Liu, K., Darrasse-Jèze, G., Guermonprez, P., Ginhoux, F., Merad, M., Shengelia, T., Yao, K., & Nussenzweig, M. (2008) · Nature Immunology · doi:10.1038/ni.1615 · Cited by 665
Normal huntingtin function: an alternative approach to Huntington's disease
Cattaneo, E., Zuccato, C., & Tartari, M. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1806 · Cited by 657
Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 650
Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
Ona, V. O., Li, M., Vonsattel, J. P. G., Andrews, L. J., Khan, S. Q., Chung, W. M., Frey, A. S., Menon, A. S., Li, X.-J., Stieg, P. E., et al. (1999) · Nature · doi:10.1038/20446 · Cited by 638
Gray, M., Shirasaki, D. I., Cepeda, C., Andre, V. M., Wilburn, B., Lu, X.-H., Tao, J., Yamazaki, I., Li, S.-H., Sun, Y. E., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0857-08.2008 · Cited by 613
O’Doherty, U., Peng, M., Gezelter, S., Swiggard, W. J., Betjes, M. G. H., Bhardwaj, N., & Steinman, R. M. (1994) · PubMed Central · Cited by 601
Neurological abnormalities in a knock-in mouse model of Huntington's disease
Lin, C.-H. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.137 · Cited by 592
Ichas, F., & Mazat, J.-P. (1998) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00119-4 · Cited by 570
Huntingtin–protein interactions and the pathogenesis of Huntington's disease
Li, S.-H., & Li, X.-J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.01.008 · Cited by 548
Structures of complement component C3 provide insights into the function and evolution of immunity
Janssen, B. J. C., Huizinga, E. G., Raaijmakers, H. C. A., Roos, A., Daha, M. R., Nilsson-Ekdahl, K., Nilsson, B., & Gros, P. (2005) · Nature · doi:10.1038/nature04005 · Cited by 541
Menalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S., & Chesselet, M. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10776 · Cited by 536
Inflammatory Neurodegeneration and Mechanisms of Microglial Killing of Neurons
Brown, G. C., & Neher, J. J. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8105-9 · Cited by 528
Penetration of interleukin-6 across the murine blood-brain barrier
Banks, W. A., Kastin, A. J., & Gutierrez, E. G. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90933-4 · Cited by 485
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity
Shin, J.-Y., Fang, Z.-H., Yu, Z.-X., Wang, C.-E., Li, S.-H., & Li, X.-J. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200508072 · Cited by 477
Microglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462 · cited 1×
“In this paradigm,microglial activation correlates with the severity of disease progression and with loss of dopamine D2 receptor binding sites [44, 45].”
BackgroundTrottier, Y., Devys, D., Imbert, G., Saudou, F., An, I., Lutz, Y., Weber, C., Agid, Y., Hirsch, E. C., & Mandel, J.-L. (1995) · Nature Genetics · doi:10.1038/ng0595-104 · Cited by 452
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease
Lobsiger, C. S., & Cleveland, D. W. (2007) · Nature Neuroscience · doi:10.1038/nn1988 · Cited by 441
Microglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440 · cited 1×
“In brains of mhtt carriers, microglia are activated even before onset of symptoms [42].”
BackgroundToll-like receptors in neurodegeneration
Okun, E., Griffioen, K. J., Lathia, J. D., Tang, S.-C., Mattson, M. P., & Arumugam, T. V. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.09.001 · Cited by 429
Huntington's disease gene (IT15) is widely expressed in human and rat tissues
Li, S.-H., Schilling, G., Young, W. S., Li, X., Margolis, R. L., Stine, O. C., Wagster, M. V., Abbott, M. H., Franz, M. L., Ranen, N. G., et al. (1993) · Neuron · doi:10.1016/0896-6273(93)90127-d · Cited by 347
Complement components of the innate immune system in health and disease in the CNS
Gasque, P., Dean, Y. D., McGreal, E. P., VanBeek, J., & Morgan, B. P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)80302-1 · Cited by 343
Singhrao, S. K., Neal, J. W., Morgan, B. P., & Gasque, P. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7170 · Cited by 316
Role of complement in neurodegeneration and neuroinflammation
BONIFATI, D., & KISHORE, U. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.007 · Cited by 313
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313
Salminen, A., Ojala, J., Kaarniranta, K., & Kauppinen, A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0962-0 · Cited by 302
Sun, Y., Savanenin, A., Reddy, P. H., & Liu, Y. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103501200 · Cited by 297
Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment
Harry, G. J., & Kraft, A. D. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.10.1265 · Cited by 295
Simmons, D. A., Casale, M., Alcon, B., Pham, N., Narayan, N., & Lynch, G. (2007) · Glia · doi:10.1002/glia.20526 · Cited by 277
Schilling, S., Goelz, S., Linker, R., Luehder, F., & Gold, R. (2006) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03094.x · Cited by 271
Self-citationMutant huntingtin and mitochondrial dysfunction
Bossy-Wetzel, E., Petrilli, A., & Knott, A. B. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.09.004 · Cited by 268
Klegeris, A., Bissonnette, C. J., & McGeer, P. L. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705304 · Cited by 246
Stack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Del Signore, S. J., Guelin, E., Ryu, H., Hersch, S. M., & Ferrante, R. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20680 · Cited by 246
van Rossum, D., & Hanisch, U.-K. (2004) · Metabolic Brain Disease · doi:10.1023/b:mebr.0000043984.73063.d8 · Cited by 234
Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Björkqvist, M., Petersén, Å., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., et al. (2007) · Journal of Proteome Research · doi:10.1021/pr0700753 · Cited by 228
Khoshnan, A., Ko, J., Watkin, E. E., Paige, L. A., Reinhart, P. H., & Patterson, P. H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2675-04.2004 · Cited by 222
Inflammation in the early stages of neurodegenerative pathology
Khandelwal, P. J., Herman, A. M., & Moussa, C. E.-H. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.07.002 · Cited by 212
Dramatic Shifts in Circulating CD4 but not CD8 T Cell Subsets in Mild Alzheimer's Disease
Larbi, A., Pawelec, G., Witkowski, J. M., Schipper, H. M., Derhovanessian, E., Goldeck, D., & Fulop, T. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1015 · Cited by 209
Ayzenberg, I., Kleiter, I., Schröder, A., Hellwig, K., Chan, A., Yamamura, T., & Gold, R. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1246 · Cited by 206
Distinct neuroinflammatory profile in post-mortem human Huntington's disease
Silvestroni, A., Faull, R. L. M., Strand, A. D., & Möller, T. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832e34ee · Cited by 203
Rajesh, M., Mukhopadhyay, P., Haskó, G., Huffman, J. W., Mackie, K., & Pacher, P. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707569 · Cited by 196
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease
Saft, C., Zange, J., Andrich, J., Müller, K., Lindenberg, K., Landwehrmeyer, B., Vorgerd, M., Kraus, P. H., Przuntek, H., & Schöls, L. (2005) · Movement Disorders · doi:10.1002/mds.20373 · Cited by 183
Self-citationVan Raamsdonk, J. M., Murphy, Z., Slow, E. J., Leavitt, B. R., & Hayden, M. R. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi407 · Cited by 180
Neuroinflammation in Huntington’s disease
Möller, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0430-7 · Cited by 177
Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice
Bradford, J., Shin, J.-Y., Roberts, M., Wang, C.-E., Sheng, G., Li, S., & Li, X.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083287 · Cited by 164
Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
Ellrichmann, G., Petrasch-Parwez, E., Lee, D.-H., Reick, C., Arning, L., Saft, C., Gold, R., & Linker, R. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016172 · Cited by 155
Self-citationImaging microglial activation in Huntington's disease
Tai, Y., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. P. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.10.029 · Cited by 155
The role of inflammasome-derived IL-1 in driving IL-17 responses
Mills, K. H. G., Dungan, L. S., Jones, S. A., & Harris, J. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012543 · Cited by 153
Huntington's disease: seeing the pathogenic process through a genetic lens
Gusella, J. F., & MacDonald, M. E. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.009 · Cited by 148
Mutant huntingtin impairs immune cell migration in Huntington disease
Kwan, W., Träger, U., Davalos, D., Chou, A., Bouchard, J., Andre, R., Miller, A., Weiss, A., Giorgini, F., Cheah, C., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64484 · Cited by 148
Taherzadeh-Fard, E., Saft, C., Akkad, D. A., Wieczorek, S., Haghikia, A., Chan, A., Epplen, J. T., & Arning, L. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-32 · Cited by 134 · cited 1×
“This hypothesis is supported by recent findings in Candida albicans, demonstrating a reduced recognition by macrophage receptors and decreased expression of cytokines such as interleukin-(IL-) 6, IL-10, and interferon-(IFN-) 𝛾 with changes in mitochondrial complex I structure [28].”
ResultBouchard, J., Truong, J., Bouchard, K., Dunkelberger, D., Desrayaud, S., Moussaoui, S., Tabrizi, S. J., Stella, N., & Muchowski, P. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4008-12.2012 · Cited by 133
Abnormal peripheral chemokine profile in Huntington’s disease
Wild, E., Magnusson, A., Lahiri, N., Krus, U., Orth, M., Tabrizi, S. J., & Björkqvist, M. (2011) · PLoS Currents · doi:10.1371/currents.rrn1231 · Cited by 119
Du, Y., Bales, K. R., Dodel, R. C., Liu, X., Glinn, M. A., Horn, J. W., Little, S. P., & Paul, S. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70031182.x · Cited by 114
Minocycline in Huntington's disease: A pilot study
Thomas, M., Ashizawa, T., & Jankovic, J. (2004) · Movement Disorders · doi:10.1002/mds.20018 · Cited by 111
Su, T., Zhao, Y. Q., Zhang, L., Peng, M., Wu, C. ‐., Pei, L., Tian, B., Zhang, J., Shi, J., Pan, H., et al. (2011) · European Journal of Pain · doi:10.1002/j.1532-2149.2011.00055.x · Cited by 97
Schwartz, M., London, A., & Shechter, R. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.12.013 · Cited by 97
Squitieri, F., Cannella, M., Sgarbi, G., Maglione, V., Falleni, A., Lenzi, P., Baracca, A., Cislaghi, G., Carsten Saft, C., Ragona, G., et al. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.010 · Cited by 96
Banati, R. B. (2002) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(02)00018-9 · Cited by 95
Boado, R. J., Hui, E. K., Lu, J. Z., & Pardridge, W. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.165092 · Cited by 93
The Inflammatory Response in Alzheimer's Disease
Rogers, J. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080171 · Cited by 92
Mitochondrial dynamics and their impact on T cell function
Quintana, A., & Hoth, M. (2012) · Cell Calcium · doi:10.1016/j.ceca.2012.02.005 · Cited by 90
Chaparro-Huerta, V., Rivera-Cervantes, M. C., Flores-Soto, M. E., Gómez‐Pinedo, U., & Beas‐Zárate, C. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.025 · Cited by 90
Efficient T-Cell Surveillance of the CNS Requires Expression of the CXC Chemokine Receptor 3
Christensen, J. E., Nansen, A., Moos, T., Lu, B., Gerard, C. J., Christensen, J. P., & Thomsen, A. R. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0123-04.2004 · Cited by 90
Acute Brain Injury Triggers MyD88-Dependent, TLR2/4-Independent Inflammatory Responses
Koedel, U., Merbt, U. M., Schmidt, C., Angele, B., Popp, B., Wagner, H., Pfister, H.-W., & Kirschning, C. J. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060821 · Cited by 78
Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease
Stüwe, S. H., Goetze, O., Lukas, C., Klotz, P., Hoffmann, R., Banasch, M., Orth, M., Schmidt, W. E., Gold, R., & Carsten Saft, C. (2013) · Neurology · doi:10.1212/wnl.0b013e318282514e · Cited by 70
Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor
Zhou, Q.-H., Sumbria, R. K., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185876 · Cited by 68
The role of immunity in Huntington's disease
Soulet, D., & Cicchetti, F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.28 · Cited by 66
The complement system in central nervous system diseases
Rus, H., Cudrici, C., David, S., & Niculescu, F. (2006) · Autoimmunity · doi:10.1080/08916930600739605 · Cited by 61
Kalathur, R. K. R., Hernández‐Prieto, M. A., & Futschik, M. E. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-47 · Cited by 47
Enhanced Th17-Cell Responses Render CCR2-Deficient Mice More Susceptible for Autoimmune Arthritis
Rampersad, R. R., Tarrant, T. K., Vallanat, C. T., Quintero-Matthews, T., Weeks, M. F., Esserman, D. A., Clark, J., Padova, F. D., Patel, D. D., Fong, A. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025833 · Cited by 46
She, X., Zhang, L., Chen, H., Calderone, R., & Li, D. (2013) · Cellular Microbiology · doi:10.1111/cmi.12135 · Cited by 43
Norflus, F., Nanje, A., Gutekunst, C.-A., Shi, G., Cohen, J., Bejarano, M., Fox, J., Ferrante, R. J., & Hersch, S. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.011 · Cited by 42
Huntington's Disease: An Immune Perspective
Nayak, A., Ansar, R., Verma, S. K., Bonifati, D. M., & Kishore, U. (2011) · Neurology Research International · doi:10.1155/2011/563784 · Cited by 39
T-cell responses to neurofilament light protein are part of the normal immune repertoire
Huizinga, R., Hintzen, R. Q., Assink, K., van Meurs, M., & Amor, S. (2009) · International Immunology · doi:10.1093/intimm/dxp011 · Cited by 25
Hertz, L., Zhao, Z., & Chen, Y. (2006) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488906775245273 · Cited by 20
Buraczyńska, M., Keuren, M. L. V., Buraczyńska, K., et al. (2008) · Cytogenetics and Cell Genetics · doi:10.1159/000134106 · Cited by 18
Research works printed but not linked: 1
- 1994, Immunology, 82, 487
Cited by
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
“[65] Ellrichmann G, Reick C, Saft C, Linker RA.”
BackgroundMicroglial M1/M2 polarization and metabolic states
Orihuela, R., McPherson, C. A., & Harry, G. J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13139 · Cited by 2,070
“, 2013; Moehle and West, 2014), Huntington disease (Ellrichmann et al., 2013; Crotti et al., 2014), amyotrophic lateral sclerosis (Evans et al.”
BackgroundBates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738
Metadata
- Authors
- Ellrichmann, G., Reick, C., Saft, C., & Linker, R. A.
- Affiliations
- St. Josef-Hospital (DE)
- Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Ellrichmann, Gisa
- Venue
- Clinical and Developmental Immunology
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-11
- ISSN
- 1740-2522 (ISSN-L)
- 1740-2530
- PMC
- PMC3727178
- OpenAlex
- W2147983580
- Cited by
- 155
- References
- 106
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 13 · 2023: 13 · 2022: 7 · 2021: 14 · 2020: 15 · 2019: 11 · 2018: 7 · 2017: 12 · 2016: 12 · 2015: 17 · 2014: 9 · 2013: 2
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Clinical and Developmental Immunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Teva Pharmaceutical Industries
- Cure Huntington’s Disease Initiative
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- Huntington's disease, neuroinflammation, innate immune system, adaptive immunity, microglial activation, macrophage migration, complement deposition, dendritic cells, T cell response, mutant huntingtin, striatum, neurodegeneration, CAG repeat expansion, peripheral immune system
- MeSH terms
- Animals, Humans, Huntington Disease, Immune System, Immunity, Innate, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.